Bifogade filer
Kurs
+3,43%
Likviditet
5,29 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-01-27 | 07:30 | Bokslutskommuniké 2025 |
2025-10-23 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-07-11 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-04-28 | N/A | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2025-04-25 | - | Årsstämma |
2025-04-24 | - | Kvartalsrapport 2025-Q1 |
2025-01-28 | - | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-12 | - | Kvartalsrapport 2024-Q2 |
2024-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2024-04-25 | - | Årsstämma |
2024-04-24 | - | Kvartalsrapport 2024-Q1 |
2024-01-25 | - | Bokslutskommuniké 2023 |
2023-10-24 | - | Kvartalsrapport 2023-Q3 |
2023-07-13 | - | Kvartalsrapport 2023-Q2 |
2023-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2023-04-25 | - | Årsstämma |
2023-04-24 | - | Kvartalsrapport 2023-Q1 |
2023-01-26 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-07-13 | - | Kvartalsrapport 2022-Q2 |
2022-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2022-04-26 | - | Årsstämma |
2022-04-25 | - | Kvartalsrapport 2022-Q1 |
2022-01-27 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-07-13 | - | Kvartalsrapport 2021-Q2 |
2021-04-23 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2021-04-22 | - | Årsstämma |
2021-04-21 | - | Kvartalsrapport 2021-Q1 |
2021-01-28 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-10-14 | - | Extra Bolagsstämma 2020 |
2020-07-10 | - | Kvartalsrapport 2020-Q2 |
2020-04-09 | - | Kvartalsrapport 2020-Q1 |
2020-04-01 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2020-03-31 | - | Årsstämma |
2020-01-30 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-07-12 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-04-24 | - | Kvartalsrapport 2019-Q1 |
2019-02-08 | - | Bokslutskommuniké 2018 |
2018-10-26 | - | Kvartalsrapport 2018-Q3 |
2018-07-13 | - | Kvartalsrapport 2018-Q2 |
2018-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2018-04-27 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-02-09 | - | Bokslutskommuniké 2017 |
2017-10-27 | - | Kvartalsrapport 2017-Q3 |
2017-07-14 | - | Kvartalsrapport 2017-Q2 |
2017-04-27 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2017-04-26 | - | Årsstämma |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-04-10 | - | Extra Bolagsstämma 2017 |
2017-02-08 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
2016-05-04 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2016-05-03 | - | Årsstämma |
2016-04-26 | - | Kvartalsrapport 2016-Q1 |
2016-02-04 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
2015-08-13 | - | Kvartalsrapport 2015-Q2 |
2015-04-24 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2015-04-23 | - | Årsstämma |
2015-04-22 | - | Kvartalsrapport 2015-Q1 |
2015-02-05 | - | Bokslutskommuniké 2014 |
2014-10-24 | - | Analytiker möte 2014 |
2014-10-24 | - | Kvartalsrapport 2014-Q3 |
2014-08-13 | - | Kvartalsrapport 2014-Q2 |
2014-04-30 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2014-04-29 | - | Årsstämma |
2014-04-23 | - | Kvartalsrapport 2014-Q1 |
2014-02-07 | - | Bokslutskommuniké 2013 |
2013-11-07 | - | Analytiker möte 2013 |
2013-11-07 | - | Kvartalsrapport 2013-Q3 |
2013-07-11 | - | Kvartalsrapport 2013-Q2 |
2013-05-08 | - | X-dag ordinarie utdelning XVIVO 0.00 SEK |
2013-05-07 | - | Årsstämma |
2013-04-19 | - | Kvartalsrapport 2013-Q1 |
2013-02-19 | - | Bokslutskommuniké 2012 |
2012-11-01 | - | Kvartalsrapport 2012-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The CHU Toulouse hospital in France has introduced both a liver and a lung machine perfusion program, now having the ability to significantly increase their transplant numbers. In a normal year they perform about 45 liver transplants and about 20 lung transplants and by that already fulfill the local requirement policy for organ transplantation. The machine perfusion programs also allow for utilization of organs donated after circulatory death (DCD).
France is the second largest transplant market in Europe. In 2020 1,112 liver transplants and 291 lung transplants were performed. The waiting list for a new liver or a new lung far exceeds the number of available organs. Machine perfusion is an innovative and proven technology to preserve and evaluate organs outside of the body which makes more donated organs accepted for transplantation.
A recent article in the American Journal of Transplantation showed that combining two commonly used protocols for liver machine perfusion using XVIVO’s Liver Assist enables safe transplantation of initially declined livers with excellent results, providing an effective tool to increase the number of suitable donor organs for transplantation[1].
“Starting two machine perfusion programs show our dedication to give more patients a life-changing transplant. Having the possibility to evaluate organs outside of the body is extremely valuable, which is not possible with traditional cold static preservation on ice. Running the ex vivo lung perfusion program I personally believe we will shorten the time on the waiting list now when more organs can be used. Initially we expect an increase in lung transplants by 20 percent”, says Pierre Rabinel, MD Thoracic Surgery at the CHU Toulouse hospital.
“It makes me very happy that CHU Toulouse starts two programs this year using XVIVO’s technologies. I would say that it is a global trend that hospitals set up machine perfusion programs for all major organs. Full perfusion centers for livers, lungs, kidneys and hearts are being established all around the world, and they are needed. For example, in 2020 only 16 percent of all donated available lungs where used. Machine perfusion will change that number”, says Dag Anderson, CEO of XVIVO.
May 19, 2022
Gothenburg
Dag Andersson, CEO
XVIVO Perfusion AB (publ)
[1] van Leeuwen, O.B., et al., Sequential Hypothermic and Normothermic Machine Perfusion Enables Safe Transplantation of High-risk Donor Livers. Am J Transplant, 2022
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.